TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TMS Co., Ltd. ( (JP:4891) ) just unveiled an update.
TMS Co., Ltd. announced significant achievements in 2024, including partnerships to advance its pipeline, such as with Corxel Pharmaceuticals for global development of JX10 for acute ischemic stroke and in-licensing TMS-010 from Hokkaido University for spinal cord injury. The company plans to initiate major clinical trials and expand its pipeline further in 2025, with ambitions to establish itself as a leader in developing treatments for high unmet medical needs. These advancements position TMS for value-creating milestones, potentially impacting its industry positioning and providing new opportunities for stakeholders.
More about TMS Co., Ltd.
TMS Co., Ltd. is a clinical-stage biopharmaceutical company that focuses on discovering and developing transformative medicines to address high unmet medical needs. The company’s pipeline includes small molecule compounds called SMTPs for treating serious diseases such as acute ischemic stroke, resistant or uncontrolled hypertension, acute kidney injury, and spinal cord injury. TMS collaborates with leading academic institutions in Japan to bridge academic discoveries and the global pharmaceutical market.
YTD Price Performance: 0%
Average Trading Volume: 546,554
Technical Sentiment Consensus Rating: Hold
Current Market Cap: Yen8.79B
For detailed information about 4891 stock, go to TipRanks’ Stock Analysis page.